Angelalign is evolving from China’s clear-aligner leader into a global orthodontic platform. Overseas expansion has grown rapidly over the past few years, but heavy upfront investment continued to weigh on earnings and obscured the underlying resilience of the core business in China. As clinical outcomes gain wider validation, Angelalign is winning greater acceptance among overseas orthodontists, with repeat usage and doctor referrals increasingly supporting case growth. Overseas operating profit turned positive for the first time in 1H26 as operating leverage kicked in. We believe the company is moving from an investment-led growth phase toward scale-driven profit expansion, with overseas markets set to become an increasingly important earnings engine.
Becoming A Valid Challenger: Since 2022, Angelalign has been investing its cash flow generated from the China business to expand overseas through local operations and selective M&A across Europe, Asia Pacific, Brazil and North America. Rather than directly challenging Invisalign as doctors’ primary brand, Angelalign has initially entered as a second supplier, supported by local sales, doctor education, clinical support and service capabilities.
Our View: Clear aligners are not a market where price alone can alter market share. Competitive barriers are built around clinical case accumulation, treatment-planning capabilities, doctor loyalty and long-term service infrastructure. Orthodontists are cautious about switching brands as they are ultimately responsible for treatment outcomes. A larger case base also strengthens treatment planning and complex-case capabilities, while better outcomes reinforce doctor confidence, repeat usage and referrals.
The barriers are even higher overseas, where successful expansion requires local sales, doctor education, clinical support, medical design and reliable fulfillment. Angelalign has vowed to build these capabilities while investing in local manufacturing to shorten delivery times and improve service responsiveness.
We are positive on the company given its ability to maintain a profitable China franchise while sustaining overseas growth. As Angelalign is transitioning from heavy investment toward harvesting, it should warrant a re-rating as overseas earnings continue to grow. The counter is trading at 49x FY26E and 31x FY27E P/E. (Research Department)